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Objectives: Precise assessment of potential therapeutic synergy, antagonism or indifference between antimicro-
bial agents currently depends on time-consuming and hard-to-standardize in vitro chequerboard titrationmeth-
ods. We here present a method based on a novel two-dimensional antibiotic gradient technique named XactTM.
Methods: We used a test comprising a combination of perpendicular gradients of meropenem and colistin in a
single quadrant. We compared test outcomes with those obtained with classical chequerboard microbroth
dilution testing in a study involving 27 unique strains ofmultidrug-resistant Acinetobacter baumannii fromdiverse
origins.
Results: We were able to demonstrate 92% concordance between the new technology and classical chequer-
board titration using the A. baumannii collection. Two strains could not be analysed by XactTM due to their
out-of-range MIC of meropenem (.128 mg/L).
Conclusions: The new test was shown to be diagnostically useful, easy to implement and less labour intensive
than the classical method.
Keywords: antibiotic resistance, susceptibility testing, two-dimensional Etest
Introduction
Treatment of patients suffering from severe infections is impacted
by the speed and accuracy of the assessment of the antimicrobial
resistance profile of the causative agent.1 Hence, the differenti-
ation between susceptible and (multi)drug-resistant bacteria is
of immediate clinical relevance. The current threat posed by mul-
tidrug resistance urges the development of laboratory methods
that document the susceptibility of certain human bacterial
pathogens to combinations of antibiotics. Combination therapy
may delay the emergence of resistance, widen the spectrum of
action of drug combinations and may also diminish the duration
of treatment. Confrontedwithmultidrug-resistant bacteria, physi-
cians may ask clinical microbiologists to supply them with such
synergy/antagonism testing data.
Whereas conventional, classical ‘chequerboard synergy test-
ing’ does provide such information, this time-consuming and
labour-intensive method cannot be easily performed on a daily
routine basis.2,3 Themethods usually lack sufficient reproducibility
and the results may be difficult to interpret.4 This is especially
evident when confronted with multidrug-resistant isolates of
Gram-negative bacterial species such as Acinetobacter bauman-
nii, Pseudomonas aeruginosa or other non-fermentative organ-
isms. In several cases, expensive clinical studies intended to
showwhether or not different drug combinations were synergistic
failed to demonstrate such an effect.5 Costs might have been
much less if such studies could have been effectively performed
in an in vitro setting. There is therefore a clear need for innovative
technologies regarding synergism or antagonism testing for com-
binations of antimicrobial agents. Newapproaches have been pro-
posed, e.g. Etest synergy assessment methods.6,7 Pankey et al.6
and Sopirala et al.7 have shown that when different combinations
and coordinations of Etests are used, some of these approaches
compare favourably with classical broth dilution-based
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chequerboard methods. However, the data presented cannot be
considered conclusive at that stage, i.e. the stage at which people
used two Etests to come to a result (since Etests were not
designed to be used in combination, the ‘double Etest approach’
could only be considered indicative and certainly not final). A new
format of the classical Etest, named XactTM, was described some
years ago and here we present a validation of that technology in a
routine clinical microbiology setting.8–11
XactTM comprises a 50×50 mm plastic carrier immobilized
with a gradient quadrant of two antibiotics of choice arranged
in perpendicular alignment, thus giving a predefined concentra-
tion patternwith hundreds of unique drug ratios in 1 or 0.5 dilution
increments. The carrier needs to be placed onto a bacteria-
inoculated agar surface and left for 1 h to transfer the gradient
imprint to the agar, after which the carrier is removed (see
Figure 1). After overnight incubation, fractional inhibitory concen-
tration indices (FICIs) are read along the inhibition isobole (see
Figure 2).12 Previously, XactTM has been compared with chequer-
board titration using bacterial isolates for several species that
were successfully tested in numerous replicates.9–11 The reprodu-
cibility of XactTM isoboles and FICI values (n¼50) was acceptable
with a standard deviation equivalent to ,25% variation from the
mean FICI value. XactTM appeared to be simple to use for the
quantification of drug–drug interactions over a wide range of
drug ratios and it was concluded that it deserved further investi-
gation as a potential tool for combination testing. To date, such
data are still lacking.
We here focused on a panel of multidrug-resistant A. bauman-
nii clinical isolates and, using an XactTM assay, tested them for
potentially synergistic susceptibility to meropenem and colistin.
We selected the combination between meropenem and colistin
since this is one of the preferred therapeutic combinations against
such strains. In addition, colistin resistance fortunately is still rare
and in combination with a carbapenem such as meropenem
therapeutic success is frequent.
Materials and methods
Strains
Escherichia coli ATCC 25922, E. coli Biodisk Culture Collection (BCC) 2,
Staphylococcus aureus ATCC 29213, Enterobacter cloacae BCC 44/75 and
Figure 1. XactTM procedure. (Top left) Inoculate: the agar surface is streaked with Retro C80TM and then dried completely. The same result can be
achieved by flooding of the plate and drying afterwards. (Top right) Apply XactTM: the XactTM quadrant is applied to the agar surface using the
vacuum pen Nema C88TM. (Bottom left) Mark XactTM position: the position is marked on the back of the plate and left in place for 1 h. (Bottom right)
Remove XactTM and incubate: the quadrant is removed after 1 h and the plate incubated, usually at 378C.
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Staphylococcus epidermidis 1-1478were used as control strains during the
preliminary validation experiments.9–11 The A. baumannii strains used in
the present validation study (n¼27) are described in Table 1. This table
shows the results of the synergy testing by chequerboard titration and
XactTM testing. Single-plex PCR assays were used to detect the following
b-lactamase genes: four carbapenem-hydrolysing oxacillinases
(blaOXA-51, blaOXA-23, blaOXA-24 and blaOXA-58), four metallo-b-lactamase
genes (blaIMP, blaVIM, blaSPM and blaNDM), blaKPC and blaGES.
(a) (b)
(c) (d)
Figure 2. Design of the XactTM combination gradient quadrant. The antibiotic gradients A and B are perpendicularly aligned. Each square equals
0.5 dilution, essentially leading to a total of 900 unique ratios of A+B. The diagonal ‘Max A to Max B’ gives a gradient ratio of A :B from 16000
(256/0.016) to 0.00006 (0.016/256). The diagonal ‘Max A/Max B to Min A/Min B’ equals a concentration gradient of A+B from 512 to 0.024 mg/L.
The FICI scale is based on calculations of FICs according to the formula: FICI¼FICA+FICB¼A(B)/ICA+B(A)/ICB, where A(B) is the lowest
concentration of A in the presence of B, and vice versa for B(A), and ICA is the concentration of A at ≤Min B, and vice versa for ICB. The scale can be
transposed in a parallel direction to read the FICI of various inhibition isoboles at different interaction points. For examples of the isoboles see (a) to (d).
(a) XactTM synergy isobole (FICI ≤0.5). (b) XactTM additive isobole (FICI .0.5 and ≤1.0). (c) XactTM indifference isobole (FICI .1.0 and ≤2.0). (d) XactTM
antagonism isobole (FICI ≥3.0).




For susceptibility testing of the A. baumannii strains, concentrations of
colistin and meropenem were applied in the XactTM format that equalled
the dilutions used in the chequerboard titrations in 2-fold dilutions in
Mueller–Hinton broth in 96-well microtitre trays. Different lots of XactTM
quadrants were used. The quadrants were stored at2208C in the presence
of desiccant.
Procedure for the chequerboard titration
Chequerboard was performed in duplo using 106 cfu/mL in Mueller–
Hinton broth (BBL). The MICs of meropenem, colistin and meropenem
plus colistin at various ratios were read and the FICI calculated. Briefly,
per round-bottomed 96-well ELISA plate, a single strain was tested and
the inoculum was set at 106 cfu/mL in Mueller–Hinton broth. The core
antibiotic stock solutions were set at 11 mg/mL for colistin and at
50 mg/mL for meropenem. Per well, 50 mL of the two antibiotic solutions
each was mixed with 100 mL of the strain suspension. After 24 h at 378C,
plates were read and the last wells without growthwere sampled to define
the true negative cultures.
XactTM procedure
Mueller–Hinton (BBL) agar plates (150 mm) were flooded or streaked with
a bacterial inoculum (a 10× diluted 0.5 McFarland suspension) and dried
completely at 358C for 15 min. The XactTM quadrant was applied to the
agar surface while its exact position was marked on the back of the
plate (Figure 1). The quadrant was removed after 1 h. The plate was incu-
bated at 358C for 16–20 h. The effect of inoculum variation (105–
109 cfu/mL) was studied with E. coli ATCC 25922. Digital pictures of the
results were transferred to a computer and interpreted using a reading
grid. Then, the demarcation zone of the isobole could be defined by clicking
on the screen. The software then automatically calculates the various
FICIs for the respective drug ratios. The program also provides a table sur-
veying all results as well as a graph showing FICI versus the ratios of the
two drugs used. Plates were also readmanually and independently by two
technicians with a grid placed on the back of the plate. Inhibition zones
provide information on synergistic, additive or antagonistic effects along
various concentration ratios of antimicrobials A and B, respectively. The
inhibition curves for meropenem and colistin were read where the inhib-
ition curvature intersected the outer edge of the grid (Figure 2). The FICI
was read where the inhibition isobologram intersected the diagonal FICI
scale with 2.0 on the scale positioned on the inhibition curve/inhibition
Table 1. Overview of the results obtained for chequerboard titrations and XactTM analysis for 27 strains of A. baumannii
No.
Chequerboard
XactTMMIC CST (mg/L) MIC MEM (mg/L) synergy/additivity
1 4 2 synergy synergy
2 4 32 additivity additivity
3 4 16 additivity synergy
4 4 32 additivity additivity
5 4 16 synergy synergy
6 8 .128 MIC MEM .128 mg/L synergy
7 4 64 synergy synergy
8 1 16 additivity additivity
9 4 32 synergy additivity
10 2 32 synergy synergy
11 4 32 synergy synergy
12 8 32 synergy synergy
13 4 32 additivity additivity
14 4 16 synergy synergy
15 2 8 synergy synergy
16 8 32 synergy synergy
17 4 32 synergy synergy
18 2 4 additivity additivity
19 2 8 synergy synergy
20 2 32 synergy synergy
21 2 8 synergy synergy
22 4 16 synergy synergy
23 4 16 additivity additivity
24 4 64 synergy synergy
25 8 16 additivity additivity
26 2 16 synergy synergy
27 4 .128 MIC MEM .128 mg/L synergy
CST, colistin; MEM, meropenem.
Strains are all epidemiologically independent. Columns indicate strain number, MICs obtained by chequerboard titration and the results of the synergy
assays. Note that in two cases, results were non-interpretable due to the elevated MIC of meropenem (.128 mg/L).
van Belkum et al.
170
curve intersection point (Figure 2). Sometimes, manual reading using a
ruler was preferred for the sake of convenience. The FICI at different anti-
biotic ratios was read by transposing the FICI scale in a parallel direction.
The area of the inhibition isobole that fell in various FICI interpretive sec-
tions showed the different types of interactions that occurred at different
meropenem/colistin ratios.
Interpretative definitions
Arbitrary definitions were defined—before experiments—as follows: when
the FICI was ≤0.5 the antibiotic combination was considered to be syner-
gistic; when the FICI was .0.5 and ≤1.0 the effect of the two antibiotics
was considered to be additive; when the FICI was.1.0 and≤2.0 the anti-
biotic interaction was indifferent; and, finally, when the FICI was ≥3.0 the
antibiotic combination was defined as antagonistic.13 When groups of
strains were compared, the two-sided Fisher exact test was used and
P,0.05 was considered to be significant.
Results
Control assays with the dedicated strains indicated that both anti-
biotics were present in an active form. Previous analyses of inocu-
lum effects on the XactTM FICI as measured for E. coli ATCC 25922
revealed that within a range between a 1:100 dilution of a 0.5
McFarland and a 5 McFarland suspension there was consistent
measurement of both the inhibition curve and the FICI. It was
concluded that at the level of XactTM, the inoculum effect was
negligible. Similar results were obtained previously with different
combinations of antibiotics.9–11
This work examined 27 multidrug-resistant A. baumannii
strains, most of them isolated from rectal swabs and all collected
between 2006 and 2013 in the Hoˆpital Universitaire de Geneve.
All study isolates were resistant to amikacin, ciprofloxacin, ceftazi-
dime and piperacillin/tazobactam. All strains were positive for
blaOXA-51, 13/27 strains carried blaOXA-23, 2/27 strains carried a
blaOXA-24-like gene and 4/27 strains had a blaOXA-58 gene.
GES-type carbapenemases were found in three strains. A strain
harbouring NDM-1 was identified from two patients. KPC, VIM,
IMP and SPM assays were uniformly negative. The MIC of imipe-
nem ranged from 0.38 to 256 mg/L. Of note, the presence of
any of these carbapenemase-encoding genes did not correlate
with whether a strain’s phenotype would show synergism or
not. The MIC of meropenem ranged from 0.5 to 256 mg/L.
Twenty-six out of 27 isolates were resistant according to
EUCAST clinical breakpoints as published for 2014. All study iso-
lates were susceptible to colistin. The MIC of colistin ranged
from 0.064 to 0.5 mg/L.
Chequerboard titration and XactTM testing revealed concordant
synergism in 16/25 strains (64%), with two strains being non-
testable due to an elevated meropenem MIC. In two strains, dis-
cordant results were obtained. Finally, 7/25 (28%) strains were
reported as additive in perfect concordance by the two methods.
Overall, 23/25 isolates (92%) for which both synergy tests were
performed successfully showed full concordance in the compari-
son between the gold standard method and XactTM.
Discussion
It has been shown by comparative in vitro testing for carbapenem-
resistant A. baumannii isolates with multiple resistance traits that
synergy between imipenem, amikacin, tobramycin and colistin
could be demonstrated for significant percentages of isolates but
not for all.14 –16 The analyses were performed by chequerboard
titration and time–kill assays and it was concluded that synergy
testing, though technically challenging, might lead to better selec-
tion of more adequate therapy. Fortunately, besides the chequer-
board titration methods for assessing synergistic activities for
antibiotic combinations, simpler alternatives have been proposed
over the past years. Still, these methods all share two big short-
comings: first, they only provide information for a fixed antibiotic
mixture; and, second, they usually require the very precise posi-
tioning of discs or strips that contain fixed amounts of gradients
of antibiotics. This is usually cumbersome and non-precise and
alternatives are still being sought. We here show that according
to chequerboard reference data, the newly developed XactTM
test showed 92% identity with the gold standard assay, a very
good level of concordance for testing of Acinetobacter strains. In
addition, underscoring the relevance of the XactTM format, not all
strains belonged to a single category of isolates, showing the rele-
vant specificity of the method. However, there was not a single
example of antagonism and if this can be verified in more exten-
sive studies, then this would suggest that a combination of colistin
and meropenem would be a good antibiotic therapy to start
with for treatment of infections caused by multidrug-resistant
Acinetobacter. In support of this suggestion, it has been demon-
strated that combination therapy with colistin and carbapenems
is among the most successful known to date.17 Finally, the con-
centrations where synergy was observed were deemed quite
compatible with the concentration range across which these anti-
biotics can be used in patients. However, in the case of the com-
bination of colistin and meropenem the XactTM format does not
allow for the precise assessment of MICs of the individual antibiotics
due to interference between the compounds. We have preliminary
evidence that the method also works for Burkholderia spp., P. aeru-
ginosa, MSSA, MRSA and a variety of other bacterial and even yeast
species (A. van Belkum,D. Halimi, E.-J. Bonetti, G. Renzi, A. Cherkaoui,
V. Sauvonnet, R. Martelin, G. Durand, S. Chatellier, G. Zombardi, A.
Engelhardt, A˚. Karlsson and J. Schrenzel, unpublished results).18
The XactTM method is easy to set up and the data generated were
convenient to analyse. The continuous and stable gradient gener-
ated high precision levels and adequate reproducibility. The test is
inherently high throughput since drug–drug interactions could be
studied across 225 or 900 drug ratios in 1 or 0.5 dilution increments.
One disadvantage is that it will remain unclear whether the effect
seen in the growth curves is due to bacteriostatic or bactericidal
activity, a feature important in the therapy of multidrug-resistant
organisms as a whole.
In comparison with chequerboard titration, XactTM allowed us
to perform three times more analyses during a similar amount of
working time, not even including the preparation time for the
plates. The assay offered clear potential and added value for rou-
tine antibiotic synergy testing and deserves further investigation
for combination testing of various drugs and organisms in differ-
ent configurations. Also, the interaction between antibiotics and
enzyme inhibitors (e.g. b-lactams and b-lactamase inhibitors) or
antibiotics and antifungals can be subjected to XactTM-mediated
analysis, although this will still require a detailed analysis of the
shelf-life of the products. Optimization of the assays can be pur-
sued via intelligent imaging and automation. Finally, the current
format offers clear opportunities for the assessment of
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interactions between antibiotics and other medications including
anticancer drugs or cardiac medication.
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